Provide feedbackProvide feedback

Home :: Pulmonary/Respiratory

Melatonin improves nighttime sleep in critically ill patients

Monday, May 12 2008 | Comments

NEW YORK (Reuters Health) - Melatonin therapy can increase the efficiency of nocturnal sleep in critically ill patients, according to a report in Critical Care published online April 18th.

Dr. Richard S. Bourne from Northern General Hospital, Sheffield, UK and colleagues examined the effect of exogenous melatonin versus placebo on nocturnal sleep in 24 patients being weaned from mechanical ventilation.

Nocturnal sleep time was 2.5 hours in the placebo group and 1 hour...

NEW YORK (Reuters Health) - Melatonin therapy can increase the efficiency of nocturnal sleep in critically ill patients, according to a report in Critical Care published online April 18th.

Dr. Richard S. Bourne from Northern General Hospital, Sheffield, UK and colleagues examined the effect of exogenous melatonin versus placebo on nocturnal sleep in 24 patients being weaned from mechanical ventilation.

Nocturnal sleep time was 2.5 hours in the placebo group and 1 hour longer in the melatonin group, the authors report, although this difference was not statistically significant.

The bispectral index (BIS) area under the curve (AUC), a measure of the quality of sleep, was significantly better in the melatonin group than in the placebo group.

"In order to get a full appreciation of the effects of melatonin on sleep in critical care patients, a continuous measure of sleep quality is probably required," Dr. Bourne said. "Although the nocturnal BIS AUC data suggested 'better' sleep after melatonin administration, polysomnography currently remains the only technique capable of providing sleep quality data."

"We would like to follow this investigation with a larger study in critical care patients using a lower dose of melatonin," Dr. Bourne commented. His team noted in the study that the 10 mg dose was probably too high as levels remained supraphysiologic in the morning.

Despite the promising results, the causes of sleep disturbances in critical care patients are multifactorial, he pointed out, so a single intervention, such as administration of melatonin, is unlikely to have a dramatic effect.

"Multicomponent interventions that include attempts to reduce environmental disturbances, ventilator dyssynchrony, and inappropriate medication, as well as attempts to reinforce a patient's circadian rhythm, are probably required," Dr. Bourne concluded.

Critical Care 2008;12:R52.

Latest News

Noninvasive mechanical ventilation may work when weaning from invasive device fails Verusmed

Thursday, May 08 2008 | Comments
NEW YORK (Reuters Health) - Noninvasive positive-pressure mechanical ventilation (NPPV) is useful in treating patients who fail weaning from invasive mechanical ventilation (IMV), according to a report in the April 17th issue of Critical Care.

As many as 30% of patients in intensive care units fail spontaneous ventilation trials, the authors explain, and in several studies NPPV has been shown to be useful, mostly among patients with chronic obstructive pulmonary disease...

Exhaled malondialdehyde: good marker of pollution exposure in pediatric asthma Verusmed

Thursday, May 08 2008 | Comments
NEW YORK (Reuters Health) - Levels of malondialdehyde, as measured by exhaled breath condensate (EBC), appear to be a useful biomarker for determining the effects of exposure to urban air pollution in children with asthma, according to a study published in the April issue of the Journal of Allergy and Clinical Immunology. The study, reportedly the first of its kind, established that malondialdehyde levels are related both to pollutant exposure and to end-organ effects, including nasal...


Add-on omalizumab improves severe persistent allergic asthma symptoms Verusmed

Wednesday, May 07 2008 | Comments
NEW YORK (Reuters Health) - Added to existing therapy, the anti-IgE antibody omalizumab improves symptoms in patients with inadequately controlled severe persistent allergic asthma, according to a report in the May issue of Allergy.

Omalizumab added to standard asthma therapies reduces exacerbations and emergency visits and improves quality of life in patients with severe persistent IgE-mediated asthma, Dr. Marc Humbert from Universite Paris-Sud, Clamart, France and colleagues...

Single controller ICS associated with lower direct total costs, asthma-related health care utilization in the year after dispensing than a number of other regimens, new data suggest Verusmed

Monday, May 05 2008 | Comments
Evidence Grade 3 What's This?
During the year after initiating treatment with a single controller inhaled corticosteroid, asthma patients incur significantly less direct total costs and asthma-related health care utilizations than those who had been dispensed a single controller leukotriene modifier or certain combination asthma controllers, researchers recently reported.

The retrospective cohort study involved comparing medical costs and health care utilization among asthma patients who used single...
Tags: Asthma